GPP is a rare and severe auto-inflammatory disease characterized by recurrent, sudden, flares of widespread painful erythema and eruption of sterile pustules.^1,2 GPP flares may lead to life-threatening multi-organ complications if left untreated hence rapid and accurate diagnosis is needed.^2,3 However, clinical presentation of GPP is heterogeneous and symptoms may resemble other skin conditions, making accurate and timely diagnosis and treatment challenging.^1,3 As there is a lack of standardized international guidelines for GPP diagnosis, the International Psoriasis Council (IPC) established a Pustular Psoriasis Working Group to address these challenges and develop an international consensus definition and diagnostic criteria for GPP.^1,3

Despite being approved for the treatment of moderate-to-severe atopic dermatitis (AD), dupilumab’s efficacy in treating patients with atopic hand and foot dermatitis had not been evaluated.^1,2 The LIBERTY-AD-HAFT trial demonstrated dupilumab’s efficacy and safety in treating patients with AD with moderate-to-severe hand and foot involvement.3 Based on the study results, the United States (US) Food and Drug Administration (FDA) updated the label of dupilumab to include AD with moderate-to-severe hand and foot involvement.⁴

Highlights Atopic dermatitis (AD) is driven by a cycle of barrier dysfunction and type 2 inflammation, with interleukin (IL)-13 playing a central role While traditional corticosteroids can control flares, they do not fully address the underlying immune-barrier interplay, l